Glp Intellectual Property Office

Glp Intellectual Property Office company information, Employees & Contact Information

GLP is a worldwide recognizable european IP firm with headquarter in Italy. The Firm was founded in 1967 and has offices in Udine, Milan, Bologna, Perugia and San Marino. The Firm specialises in the protection and enforcement of IP rights in Europe, Italy and abroad. GLP also provides assistance with regard to infringement and competition issues, to either plaintiffs or defendants Clients. We assist Clients on matters of secrecy, and evaluate whether inventive ideas and trade marks can be protected. Our Clients range from the small company to the large multinational companies. The Firm guarantees quick and high quality services. The level of the service is the firm's business card.

Company Details

Employees
67
Founded
-
Address
Via Victor Hugo, 2, Milan,lombardy 20123,italy
Industry
Legal Services
NAICS
Legal Services
Offices of Notaries
Other Legal Services
Title Abstract and Settlement Offices
All Other Legal Services
Website
glp.eu
HQ
Milan, Lombardy
Looking for a particular Glp Intellectual Property Office employee's phone or email?

Glp Intellectual Property Office Questions

News

EMA partners with content creators to promote safe and responsible use of GLP-1 medicines - European Medicines Agency

EMA partners with content creators to promote safe and responsible use of GLP-1 medicines European Medicines Agency

GLP-1 Use in Europe Hampered by Stigma and Cost - Medscape

GLP-1 Use in Europe Hampered by Stigma and Cost Medscape

Did Novo open the Canadian market to GLP-1 generics? - Labiotech.eu

Did Novo open the Canadian market to GLP-1 generics? Labiotech.eu

Novo Nordisk’s Rybelsus Becomes First EU Approved Oral GLP-1 Reducing Severe Cardiovascular Events - Pharmaceutical Executive

Novo Nordisk’s Rybelsus Becomes First EU Approved Oral GLP-1 Reducing Severe Cardiovascular Events Pharmaceutical Executive

Novo Nordisk’s GLP-1 pill gets EU approval for cardiovascular benefits - Sherwood News

Novo Nordisk’s GLP-1 pill gets EU approval for cardiovascular benefits Sherwood News

EU approval makes Novo Nordisk’s oral semaglutide the first - GlobeNewswire

EU approval makes Novo Nordisk’s oral semaglutide the first GlobeNewswire

How is GLP-1 changing eating habits in Europe? - FoodNavigator.com

How is GLP-1 changing eating habits in Europe? FoodNavigator.com

EU approval makes Novo Nordisk’s oral semaglutide first and only oral GLP-1 RA to reduce cardiovascular death, heart attack, and stroke - PharmaLive

EU approval makes Novo Nordisk’s oral semaglutide first and only oral GLP-1 RA to reduce cardiovascular death, heart attack, and stroke PharmaLive

Warning about sharp rise in illegal medicines sold in the EU - European Medicines Agency

Warning about sharp rise in illegal medicines sold in the EU European Medicines Agency

GLP to establish €2 billion partnership with CPPIB and Quadreal - CPP Investments

GLP to establish €2 billion partnership with CPPIB and Quadreal CPP Investments

Patients Using Popular Meds May Face a Tariff Hit: US–EU Trade Deal Targets Branded Drugs Like Ozempic and Wegovy - Cato Institute

Patients Using Popular Meds May Face a Tariff Hit: US–EU Trade Deal Targets Branded Drugs Like Ozempic and Wegovy Cato Institute

EU regulator finds no link between GLP-1s and suicidal thoughts - Fierce Pharma

EU regulator finds no link between GLP-1s and suicidal thoughts Fierce Pharma

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits - NeurologyLive

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits NeurologyLive

Novo Warns EU of GLP-1 Drug Shortages, Expands Production at French Site - BioSpace

Novo Warns EU of GLP-1 Drug Shortages, Expands Production at French Site BioSpace

GLP-1 drugs just made WHO’s essential list — here’s what it means - Labiotech.eu

GLP-1 drugs just made WHO’s essential list — here’s what it means Labiotech.eu

Europe Acts to Address GLP-1 Drug Shortages - Medscape

Europe Acts to Address GLP-1 Drug Shortages Medscape

EU actions to tackle shortages of GLP-1 receptor agonists - European Medicines Agency

EU actions to tackle shortages of GLP-1 receptor agonists European Medicines Agency

How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market - Labiotech.eu

How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market Labiotech.eu

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 - European Medicines Agency

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 European Medicines Agency

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024 - European Medicines Agency

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024 European Medicines Agency

EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts - Reuters

EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts Reuters

Sublingual delivery: the future for GLP-1 receptor agonists - Labiotech.eu

Sublingual delivery: the future for GLP-1 receptor agonists Labiotech.eu

GLP-1s in the spotlight at Vitafoods Europe conference - Food Business News

GLP-1s in the spotlight at Vitafoods Europe conference Food Business News

Novo Nordisk, Eli Lilly face scrutiny from EU's drug regulator over GLP-1 safety - Fierce Pharma

Novo Nordisk, Eli Lilly face scrutiny from EU's drug regulator over GLP-1 safety Fierce Pharma

European regulators want to know more about the risks of GLP-1 drugs - BioPharma Dive

European regulators want to know more about the risks of GLP-1 drugs BioPharma Dive

EU taking action to tackle GLP-1 receptor agonist shortages - The Pharma Letter

EU taking action to tackle GLP-1 receptor agonist shortages The Pharma Letter

Can GLP-1 agonists help treat addiction? - Labiotech.eu

Can GLP-1 agonists help treat addiction? Labiotech.eu

GLP-1 agonists: what’s the hype about? - Labiotech.eu

GLP-1 agonists: what’s the hype about? Labiotech.eu

GLP-1 shortage: Can biotech companies keep up with rising demand? - Labiotech.eu

GLP-1 shortage: Can biotech companies keep up with rising demand? Labiotech.eu

Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research - GlobeNewswire

Europe Glucagon-like Peptide-1 (GLP-1) Agonists Research GlobeNewswire

EU starts media campaign to encourage safe GLP-1 use - Anti-counterfeiting news

EU starts media campaign to encourage safe GLP-1 use Anti-counterfeiting news

Six biotech companies that could revolutionize obesity treatments - Labiotech.eu

Six biotech companies that could revolutionize obesity treatments Labiotech.eu

No Evidence New Weight Loss Drugs Cause Thyroid Cancer, EU Agency Finds - Bloomberg

No Evidence New Weight Loss Drugs Cause Thyroid Cancer, EU Agency Finds Bloomberg

European Union takes giant leap forward toward embracing technologically-enhanced agriculture, advances de-regulation of gene edited crops - Genetic Literacy Project

European Union takes giant leap forward toward embracing technologically-enhanced agriculture, advances de-regulation of gene edited crops Genetic Literacy Project

CordenPharma Expands GLP-1 Manufacturing Footprint in US and Europe with $980M Commitment - BioSpace

CordenPharma Expands GLP-1 Manufacturing Footprint in US and Europe with $980M Commitment BioSpace

German CDMO outlays $980m on GLP-1 manufacturing expansion - Pharmaceutical Technology

German CDMO outlays $980m on GLP-1 manufacturing expansion Pharmaceutical Technology

GLP racks up 1.2bn euros for third European logistics income fund - Buyouts

GLP racks up 1.2bn euros for third European logistics income fund Buyouts

Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next - qz.com

Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next qz.com

CordenPharma to invest $980M in US, Europe GLP-1 capacity - Manufacturing Dive

CordenPharma to invest $980M in US, Europe GLP-1 capacity Manufacturing Dive

GLP-1 supplements: the future of weight management nutrition - New Food magazine

GLP-1 supplements: the future of weight management nutrition New Food magazine

GLP-1 drugs not linked to suicidal thoughts, EU drug regulator finds - Medical News Today

GLP-1 drugs not linked to suicidal thoughts, EU drug regulator finds Medical News Today

What To Know About Aspiration After EU Warns Of The Anesthesia Risk From GLP-1 Drugs - Forbes

What To Know About Aspiration After EU Warns Of The Anesthesia Risk From GLP-1 Drugs Forbes

First oral GLP-1 treatment for type 2 diabetes - European Medicines Agency

First oral GLP-1 treatment for type 2 diabetes European Medicines Agency

Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market - Sifted

Riding the Wegovy wave: The startups shifting focus to GLP-1s to tap the $150bn weight loss drug market Sifted

GLP-1 drugs like Ozempic set to shake the global food industry - FoodNavigator.com

GLP-1 drugs like Ozempic set to shake the global food industry FoodNavigator.com

GLP Europe Clean Energy continues to expand the team - BDC Magazine

GLP Europe Clean Energy continues to expand the team BDC Magazine

Barclays sees growing risks for EU food ingredients producers driven by GLP-1 medications - TradingView

Barclays sees growing risks for EU food ingredients producers driven by GLP-1 medications TradingView

Rybelsus, the First GLP-1 Pill, Approved for Type 2 Diabetes in Europe - Making Sense of Diabetes

Rybelsus, the First GLP-1 Pill, Approved for Type 2 Diabetes in Europe Making Sense of Diabetes

GLP Raises €1.6 Bil for GLP Europe Income Partners II - Mingtiandi

GLP Raises €1.6 Bil for GLP Europe Income Partners II Mingtiandi

GLP sells Spanish logistics from pan-European fund to EQT Exeter - IPE Real Assets

GLP sells Spanish logistics from pan-European fund to EQT Exeter IPE Real Assets

London startup raises $410m in one of Europe’s biggest ever Series A rounds as it joins weight loss drugs frenzy - Sifted

London startup raises $410m in one of Europe’s biggest ever Series A rounds as it joins weight loss drugs frenzy Sifted

Gazeley adopts GLP brand as the latter acquires CEE portfolio - Transport Intelligence

Gazeley adopts GLP brand as the latter acquires CEE portfolio Transport Intelligence

GLP Raises $1.3B for GLP Europe Income Partners II - Mingtiandi

GLP Raises $1.3B for GLP Europe Income Partners II Mingtiandi

GLP appoints Natali Cooper to lead ESG in Europe - IPE Real Assets

GLP appoints Natali Cooper to lead ESG in Europe IPE Real Assets

Investigation into GLP-1-based diabetes therapies concluded - European Medicines Agency

Investigation into GLP-1-based diabetes therapies concluded European Medicines Agency

CPPIB forms $1.5-billion EU logistics partnership with GLP and QuadReal - The Globe and Mail

CPPIB forms $1.5-billion EU logistics partnership with GLP and QuadReal The Globe and Mail

SGS Opens New GLP Testing Stations in Poland - AgriBusiness Global

SGS Opens New GLP Testing Stations in Poland AgriBusiness Global

GLP completes work on G-Park Zevenaar, one of Europe’s largest renewable energy installations - BDC Magazine

GLP completes work on G-Park Zevenaar, one of Europe’s largest renewable energy installations BDC Magazine

Gazeley becomes GLP in Europe and completes €1b CEE deal - IPE Real Assets

Gazeley becomes GLP in Europe and completes €1b CEE deal IPE Real Assets

Arendt & Medernach advises GLP - Paperjam

Arendt & Medernach advises GLP Paperjam

Top Glp Intellectual Property Office Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant